Skip to main content
Event

Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026

Monday, January 12, 2026
Sidley Speakers
Torrey CopeMeenakshi DattaSally Wagner Partin

Event Details

DateMonday, January 12, 2026

11:30 a.m. - 2:30 p.m. PT

For questions, please contact sfevents@sidley.com.

Join members of Sidley's Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.

Led by Meena Datta, global co-leader of Sidley's Healthcare practice; Torrey Cope, partner in Sidley's Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley's M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.

Contacts

Cope, Torrey
パートナー
Datta, Meenakshi
パートナー
Wagner Partin, Sally
パートナー

Offices

Related Resources

Capabilities

Suggested News & Insights

EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 18, 2025
Global Life Sciences Update
EU Biotech Act: EU Proposes First Set of Rules to Facilitate Biopharmaceutical CompetitivenessThursday, December 18, 2025
Global Life Sciences Update
Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025
Announcements
First Chair Trial and Leading Product Liability Lawyer Paul Boehm Joins Sidley as Partner in D.C. to Expand Product Liability and Mass Torts Litigation PracticeDecember 18, 2025
Press Releases
Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025
Announcements
Sidley Represents Apollo Funds in Majority Investment in Prosol GroupDecember 16, 2025
Announcements